Fig. 7

DC661 overrode adaptive resistance to sorafenib in vitro. A Cell viability after treatment with different DC661 concentrations for 48 h was determined by CCK-8 assay. B IC50 values for DC661 in Hep 3B-SR and Hep 1-6-SR cells according to (A) were determined by CCK-8 assay. The data shown are from three independent experiments. C Cell viability in HCC cells after treatment with sorafenib (1.5 µM) and/or DC661 (0.5 µM) for 48 h was determined by CCK-8 assay. *P < 0.05; **P < 0.01; ***P < 0.001. D Flow cytometric analysis of cell apoptosis and necrosis in HCC cells treated with sorafenib (1.5 µM) and/or DC661 (0.5 µM) for 48 h. E For the colony formation assay after sorafenib (1.5 µM, 48 h) and/or DC661 (0.5 µM, 48 h) therapy, HCC cells were first seeded into a 6-well plate at a density of 1000 cells/well and routinely cultured for 14 days, then stained with crystal violet and imaged